Pmo-based utrophin::let-7c mirna site blocking oligonucleotides (sbos) for treating duchenne muscular dystrophy (dmd)
AssigneeThe Trustees of the University of Pennsylvania
InventorTejvir S. S. KHURANA
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions for enhancing utrophin protein production by inhibiting binding of a Let-7c microRNA molecule to its binding site in the utrophin mRNA 3′-untranslated region (UTR). In particular, phosphorodiamidate morpholino oligonucleotide (PMO) site blocking oligonucleotides (SBOs) that inhibit Let-7c miRNA binding to its binding site in the utrophin mRNA 3′UTR. Moreover. methods of enhancing utrophin protein production in muscle cells can be used to treat muscular dystrophy and/or other myopathies.
Claims19
A method of treating Duchenne Muscular Dystrophy (DMD) in a human subject, the method comprising administering to said subject an effective amount of an oligonucleotide that (i) specifically hybridizes to a Let-7e microRNA binding sequence in a utrophin mRNA 3′-untranslated region (UTR) and (ii) inhibits binding of a Let-7c microRNA to the utrophin mRNA 3′-UTR.
A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and an oligonucleotide that specifically hybridizes to a Let-7c microRNA binding sequence in a utrophin mRNA 3′-untranslated region (UTR), wherein the oligonucleotide is present in an amount effective in a human subject to inhibit binding of Let-7 microRNA to its utrophin mRNA 3′-UTR.
A method for enhancing utrophin production in a subject, the method comprising administering to said subject an oligonucleotide that (i) specifically hybridizes to a Let-7c microRNA binding sequence in a utrophin mRNA 3′-untranslated region (UTR) and (ii) inhibits binding of a Let-7c microRNA to the utrophin mRNA 3′-UTR.
Dependencies are inferred from the claim text.